Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low-dose rituximab for pemphigus (real-world observational study)
ChiCTR2500106964Phase 4Recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in pemphigus, sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoints: Pemphigus Disease Area Index (PDAI) and Complete remission on minimal therapy (CRmin). Started Aug 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
pemphigus
Beyond the preview
Go deeper on ChiCTR2500106964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106964.